December 22, 2024

Monkeypox Business: Bill Gates Again Becomes the High Priest of the Monkeypox Narrative as he did for Covid

Politico released a special report highlighting how Bill Gates, lacking any medical qualifications, came to dominate the global response to COVID-19 with minimal oversight.

During the initial phase of the pandemic, four non-governmental organizations (NGOs) collaborated to pinpoint vaccine manufacturers and make strategic investments in the creation of tests, treatments, and vaccines, as noted by Politico.

These organizations included the Bill & Melinda Gates Foundation, Gavi (a Gates initiative focused on providing vaccines to developing countries), the Wellcome Trust (a British research foundation led by Dr Jeremy Farrar,  who has now been appointed as the WHO’s chief scientist), and the Coalition for Epidemic Preparedness Innovations (CEPI), an international vaccine research and development entity co-founded by Gates and Wellcome in 2017.

Working alongside the WHO, these four NGOs—three of which were established by Gates—developed a global distribution strategy for the tests, medications, and vaccines they had funded.

https://qvive.in/world-news/monkeypox-will-now-be-known-as-mpox-by-the-who-due-to-us-pressure
https://qvive.in/world-news/a-big-pharma-company-supported-by-the-bill-and-melinda-gates-foundation-is-using-the-same-pcr-test-for-monkeypox-that-was-used-for-covid-19

BILL GATES AND WHO GEARING UP FOR THE NEXT ‘PANDEMIC’ – SEERS VIRUS SET FOR 2025

THE BILL & MELINDA GATES FOUNDATION HAS JOINED FORCES WITH THE WORLD HEALTH ORGANIZATION AND JOHNS HOPKINS UNIVERSITY CENTER FOR HEALTH SECURITY AT A RECENT GATHERING IN BELGIUM.

On October 23, 2022, a significant event took place as Gates, Johns Hopkins, and the World Health Organization collaborated to host a global challenge exercise known as “Catastrophic Contagion.” This exercise revolved around a new and currently fictional pathogen referred to as “severe epidemic enterovirus respiratory syndrome 2025,” abbreviated as SEERS-25.

Enterovirus D685 is commonly linked to cold and flu-like symptoms in infants, children, and teenagers. Although rare, it can also lead to serious conditions such as viral meningitis and acute flaccid myelitis, which is characterized by muscle weakness and diminished reflexes in one or more limbs.

Additionally, enteroviruses A71 and A6 are recognized for causing hand, foot, and mouth disease, while the well-known poliovirus leads to polio (poliomyelitis), a severe form of paralysis that predominantly affects young children under five. Therefore, the virus simulated in this exercise seems to resemble enterovirus D68 but poses an even greater threat.

Catastrophic Contagion Highlights Reel

Participants engaged in a ‘table-top simulation’ that envisioned a lethal enterovirus emerging from South America in 2025, with the potential to spread globally and claim millions of lives. This virus, particularly threatening to children, is classified within the polio virus family.

Dubbed SEERS – Severe Epidemic Enterovirus Respiratory Syndrome, this exercise in Belgium has drawn parallels to the notorious Event 201, where the same organizations conducted simulations of a ‘flu-like’ pandemic in October 2019, just two months prior to the initial COVID cases reported in China.

The independent news outlet Redacted examined Gates’ recent ‘virus preparedness clinic.’ The software engineer and former college student has reportedly reaped a tenfold return on his investments in health and vaccine technology before the COVID crisis, transforming $10 billion into $200 billion, which he has labeled as his ‘best investment.’

It’s starting, Bill Gates announces the next pandemic date and outbreak location | Redacted News

The mpox emergency and the role of Gavi

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world’s deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organisations that fund Gavi’s work here.

With India’s strong economic growth and increased presence and visibility (BRICS member) on the international stage, India has become an emerging donor of aid. India sees its development assistance programmes as different from traditional “donor-recipient relationships” and stresses the aspect of “development partnership”. It is considered that development aid is part of India’s long-term strategic and economic objectives.

In 2014, India became the first implementing country donating to Gavi; committing US$ 4 million over a four-year period from 2013–2016.

In 2018, India doubled its contribution to Gavi, committing US$ 8 million for the four-year period from 2018–2022. Prime Minister Modi has emerged as a leading champion for immunisation in India and globally, enabling India to accelerate its efforts in driving towards universal immunisation.

At the Global Vaccines Summit on 4 June 2020, PM Modi pledged US$ 15 million for Gavi’s 2021–2025 programme.

Union Health Minister Dr. Harsh Vardhan was nominated as a member to the Board of GAVI, The Vaccine Alliance

Now Mpox outbreak: A great chance for India to start making vaccines.

Recently, there has been a surge in global monkeypox cases reported in the news, with mainstream media emphasizing these headlines to capture public attention.

The Union Cabinet’s recent decision to implement a high-performance biomanufacturing policy under BioE3 is expected to attract INR 10,000 crore in investments. This initiative aims to enhance vaccine manufacturing, significantly boosting India’s bioeconomy from US$ 10 billion to US$ 130 billion over the past decade and strengthening health security. The Indian Vaccine Manufacturers Association has also emphasized India’s commitment to improving healthcare in Africa and meeting global regulatory standards. By promoting vaccine production through public-private partnerships and international collaborations, India can advance its leadership in global health initiatives.

The World Health Organization has urged manufacturers to boost production of mpox diagnostic kits under the Emergency Use Listing, especially due to limited vaccine availability. The Democratic Republic of the Congo reported 1,000 suspected mpox cases this week, underscoring the urgent need for effective diagnostics, particularly in low- and middle-income African countries. In a positive development, India’s Central Drugs Standard Control Organisation has approved domestically developed mpox diagnostic kits validated by the Indian Council of Medical Research, enhancing resilience during the ongoing Public Health Emergency of International Concern.

Related Article:

https://qvive.in/world-news/covid-19-monkeypox-pcr-tests-are-scientifically-meaningless

The Lancet: The Aug 13, 2024 declaration by the Africa Centres for Disease Control and Prevention (Africa CDC) that mpox is a public health emergency of continental security1,2 and WHO’s Aug 14, 2024 declaration of an mpox public health emergency.

At Gavi, the Vaccine Alliance, we have been carefully taking stock of the worrying impacts of the clade 1 outbreak in DR Congo and the spread of mpox cases to neighbouring countries and beyond and have internally aligned on four specific priority areas where our partnership model can support a coordinated response.10,11

The first is procurement of mpox vaccine doses. Currently there are two vaccines in use, as recommended by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE). These will require funding, and this is where Gavi’s First Response Fund (FRF) could contribute to the response; this fund was set up in response to lessons from COVID-19.

The FRF has been set up following final approval by the Gavi Board in June, 2024. Gavi is also working towards the establishment of an emergency stockpile of mpox vaccine doses to address the longer-term public health needs. The commitment to fund vaccine stockpiles is an effective way of incentivising manufacturers to continue investing in vaccine supply, even when vaccine demand for outbreak response is unpredictable. Gavi is in close conversation with WHO and manufacturers on expected timelines for regulatory approvals, as Gavi is only able to procure vaccines once they have been prequalified or have been granted Emergency Use Listing by WHO, while doing all necessary preparatory work.

Bill Gates is reportedly developing diagnostic tools and a vaccine for monkeypox, potentially setting the stage for the next pandemic, similar to his involvement with COVID-19

Gavi’s statement on MPOX emergency in Africa

15 August 2024 – Gavi, the Vaccine Alliance continues to be deeply concerned about the escalating mpox emergency on the African continent. We welcome recently announced measures by our partners at the African Centres for Disease Control and Prevention (Africa CDC) and World Health Organization (WHO) which will help create an enabling environment in support of a comprehensive region-led response, and join partners in emphasizing the importance of international coordination following a declaration of a Public Health Emergency of Continental Security by Africa CDC and a Public Health Emergency of International Concern by WHO.

 Gates Becoming the High Priest of the Monkeypox Narrative:

Gavi pushing forward for a robust Pandemic Agreement.

https://www.gavi.org/vaccineswork/mpox-outbreak-one-more-reason-we-need-strong-pandemic-agreement

How the Pandemic Agreement can help

The global health community has been actively engaged in negotiations for a Pandemic Agreement – a comprehensive, binding framework under the WHO constitution intended to better prevent, prepare for, and respond to future pandemics. The Agreement presents a unique opportunity to take the lessons learned from past outbreaks like COVID-19, and the current mpox outbreak, to ensure the world is better equipped for future health security threats. The Agreement, once adopted, could lead to significant health security improvements on several fronts:

  1. Increasing equitable access to vaccines, therapeutics and diagnostics: The COVID-19 pandemic underscored the dangers of uneven access to vaccines and other essential medical countermeasures. This inequity is precisely what the Pandemic Agreement seeks to address through the Pathogen Access and Benefit Sharing system – establishing an equitable system for access and distribution from the outset in real time, regardless of income level. Gavi’s experience with COVID-19 and other outbreaks show that an equitable system agreed upon by all Member States is and will continue to be critical for stopping the spread of infectious diseases worldwide.
  2. Strengthened surveillance and early warning systems: One of the most significant factors in addressing the mpox outbreak is, and will continue to be, strong surveillance and early warning systems. Effective pandemic preparedness requires real-time data sharing, coordinated responses, and the ability to rapidly detect and track emerging pathogens, particularly as they spread across borders. The Pandemic Agreement could play a key role in increasing investments in global surveillance infrastructure, including sharing of pathogen information and genomic sequencing. Such measures, alongside strong investments in the health workforce that are a pivotal part of the Agreement, are critical for stopping outbreaks before they spread into global health emergencies.
  3. Sustainable financing for prevention, preparedness, and response: Sustainable, long-term investment and a well-coordinated global governance structure are critical to successfully limiting the chances of an outbreak, and being sufficiently responsive when a pandemic occurs. The proposed Pandemic Agreement establishes dedicated coordinating financial mechanisms and frameworks that would help countries to prioritize investments in key capacities.
https://www.gavi.org/vaccineswork/tag/mpox

Even if you’re living with a person infected with monkeypox, your risk of catching the disease is surprisingly low, says biologist Joseph Osmundson. Preliminary data, with a small number of cases, found that the chance of spreading monkeypox to a household member, not through sex, is only about 0.6%.

https://www.npr.org/sections/goatsandsoda/2022/08/05/1115859376/clearing-up-some-of-the-myths-that-have-popped-up-about-monkeypox

10 September 2024 – A shipment of 15,460 doses of mpox vaccine, donated to Gavi-eligible countries by the vaccine manufacturer Bavarian Nordic, arrived in the Democratic Republic of the Congo (DRC) today to support the global and regional effort to contain the outbreak. The doses landed in Kinshasa, the country’s capital. They add to the 215,000 vaccine doses that the European Union donated to the country last week.

https://www.gavi.org/news/media-room/15000-mpox-vaccine-doses-arrive-democratic-republic-congo

WHO Approves First Mpox Vaccine for Adults in Africa — Then Says Babies Can Get It, Too, Despite No Clinical Trials.

September 13, 2024: The World Health Organization has officially approved the first mpox vaccine, a crucial step in enhancing the global response to this disease, particularly in Africa.

The vaccine’s pre-qualification by Bavarian Nordic A/S opens the door for organizations like GAVI the Vaccine Alliance and UNICEF to purchase it.

Health Officials Push Mpox Vaccine After Bavarian Nordic’s FDA-Approved Shot Hits Commercial Market

FDA Confesses: Zero Scientific Evidence of “Monkeypox Virus” or Contagion… Not Even a “Genome” Found by Anyone… Anywhere

Sarah B. Kotler (“J.D.”) acting as Director, Division of Freedom of Information, US Food and Drug Administration (FDA) officially confirmed that the people running the FDA have no records authored by anyone, anywhere regarding the monkeypox virus

1. that scientifically prove/provide evidence of the existence of any alleged monkeypox virus“, or

2. that even describes the purification of particles that are alleged to be “monkeypox virus” directly from bodily fluid/tissue/excrement of so-called “hosts”, or

3. that describe the purported “genome” of any alleged “monkeypox virus” being found intact in the bodily fluid/tissue/excrement of a so-called “host” (as opposed to fabricated in silico, aka a computer model), or

1. that scientifically prove/provide evidence of the existence of any alleged monkeypox virus“, or

2. that even describes the purification of particles that are alleged to be “monkeypox virus” directly from bodily fluid/tissue/excrement of so-called “hosts”, or

3. that describe the purported “genome” of any alleged “monkeypox virus” being found intact in the bodily fluid/tissue/excrement of a so-called “host” (as opposed to fabricated in silico, aka a computer model), or

4. that scientifically demonstrate contagion of the illness / symptoms that are allegedly caused by purported “monkeypox viruses” [see pg 6].

Sadly, it looks like logic still isn’t Sarah’s thing, because in her  email she wrote (not for the 1st time) (pg 6):

“The FDA does not regulate or treat viruses. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation’s food supply, cosmetics, and products that emit radiation. Therefore, we have no responsive records.” (emphasis added)

This, despite the fact that “experts” at the FDA approved a quackcine to “prevent monkeypox disease”, are complicit in “Emergency Use Authorizations” of “in vitro diagnostics… related to monkeypox” and provide “Information for Monkeypox Test Developers”, etc.

Many more failed FOI responses relating to the fake/false/fraudulent “monkeypox virus” narrative can be found here.

Challenge to “W.H.O.”, etc. re “monkeypox virus” fraud/delusion… + FOI evidence + a summit

Ref: https://christinemasseyfois.substack.com/p/challenge-to-who-etc-re-monkeypox

CDC: Low risk of catching Monkeypox on air travel with infected people

The Centers for Disease Control (CDC) recently concluded investigations related to the spread of monkeypox (Clade II) during air travel in the US between July 2021 and August 2022. Among more than 1,000 traveler contacts on commercial flights monitored by health departments, no secondary cases of monkeypox were identified. The CDC concludes there is low risk of getting monkeypox by flying on an airplane with infected people.

The following information is from CDC.

Since May 2022, approximately 33,000 mpox cases have occurred in the United States*; most patients have experienced painful skin lesions, typically in the anogenital region, and some have suffered life-threatening complications or protracted illness.

Key Findings:

  • Over 113 people flew on 221 commercial flights while infectious with monkeypox.
  • 1,046 contacts were traced, but no secondary cases of monkeypox were identified.
  • The CDC’s findings align with those of a similar investigation conducted by Australian public health authorities in 2022. Both studies concluded that the risk of monkeypox transmission on airplanes is very low, even in cases where cabin crew members had monkeypox.

Ref: https://sharylattkisson.com/2024/09/cdc-no-transmission-of-monkeypox-linked-to-air-travel/

Concerns Over Cardiac Side Effects from Monkeypox Vaccination

By Peter A. McCullough, MD, MPH

Monkeypox vaccines include ACAM2000 (used for Smallpox, recently FDA approved for Monkeypox), JYNNEOS, and modified vaccinia Ankara. The at-risk population is young men who are at the highest risk of idiopathic and COVID-19 vaccine myocarditis at baseline. ACAM2000 has been reported to have major cardiovascular adverse events such as myocarditis, dilated cardiomyopathy, and heart failure. Whereas JYNNEOS and modified vaccinia Ankara are associated with minor cardiovascular adverse events such as tachycardia, palpitation, electrocardiogram changes such as T wave inversion, and ST elevation in the peer-reviewed literature. The CDC has reported serious myocarditis from the Bavarian Nordic JYNNEOS vaccine requiring hospitalization of young men. 

Ref: https://petermcculloughmd.substack.com/p/concerns-over-cardiac-side-effects

The deadly and harmful ingredients of the monkeypox (mpox) vaccine

The monkeypox (mpox) ACAM2000 vaccine uses the antibiotics neomycin and polymyxin B, alongside other components like the live vaccinia virus, HEPES, human albumin, mannitol and diluent nasties.

There are adverse reactions linked to these vaccine components as Dr. Geoff Pain points out while raising several concerns about the safety and potential adverse effects of Emergent BioSolutions’ smallpox vaccine that has been repurposed for mpox.

Why are antibiotics contained in ACAM2000?  Dr. Pain speculates that these components are included to address potential bacterial contamination and endotoxin release.

Ref: https://expose-news.com/2024/09/16/harmful-ingredients-of-the-monkeypox-mpox-vaccine/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389550/

Editors Note: Throughout the COVID plandemic, a familiar narrative has emerged from mainstream media and government health ministries in India. It’s striking to observe that each time a virus outbreak occurs—be it COVID, Nipah, dengue, or now monkeypox—the initial isolation and quarantine measures are consistently implemented in Kerala. This pattern raises suspicions among the public across India, leading many to question whether the Kerala government is somehow involved in a larger plandemic agenda.

Source: Global Research, youtube, Children’s Health Defence

Related Post